Pleiotropic effects of cardilopin (secondary coronary prevention).
In order to evaluate some pleiotropic effects of cardilopin (Amlodipine, EGIS Pharmaceuticals) 33 ambulatory patients were examined. During the 2-month study period on the background of cardilopin treatment there were positive changes in some parameters of coronary atherosclerosis. Pleiotropic effects of cardilopin were particularly expressed in restoring of endothelial function and inhibition of platelet aggregation. There was found tendency to reduce the degree of hyperlipoperoxidemia related to oxidative stress. Obtained results of the present trial support the use of cardilopin in all coronary heart disease patients with or without myocardial revascularization and arterial hypertension.
Kapanadze
S
S
Dolidze
N
N
Bakhutashvili
Z
Z
Chapidze
L
L
Shengelia
E
E
D017311:Amlodipine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D015924:Blood Pressure Monitors; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000502:physiology; D006339:Heart Rate; D006801:Humans; D008054:Lipid Peroxides / Q000097:blood; D009569:Nitric Oxide / Q000097:blood; D018384:Oxidative Stress; D010974:Platelet Aggregation / Q000187:drug effects; D013997:Time Factors; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D002121:Calcium Channel Blockers; D008054:Lipid Peroxides; D014665:Vasodilator Agents; D017311:Amlodipine; D009569:Nitric Oxide